Proactive Investors - Run By Investors For Investors

Hemispherx Biopharma updates terms of $8 million rights offering, says senior management is participating

The pricing remains $1,000 per unit, consisting of one share of Series B convertible preferred stock, and warrants
cancerous cells
Hemispherx’s flagship product is the Argentina-approved Ampligen, which treats chronic fatigue syndrome and cancer

Hemispherx Biopharma Inc (NYSE American: HEB) said Wednesday that it has adjusted certain pricing information for its announced $8 million rights offering, which will be used to fund trials for its anti-cancer agent Ampligen.

The pricing remains $1,000 per unit, consisting of one share of Series B convertible preferred stock with a stated value of $1,000 (and immediately convertible into Hemispherx’s common stock) and warrants to purchase Hemispherx’s common stock.

But the Series B convertible preferred stock conversion price will now be $0.20 and each unit will now consist of 5,000 warrants to purchase Hemispherx’s common stock at an adjusted exercise price of $0.20. The warrants will be exercisable for five years after the date of issuance.

READ: Hemispherx Biopharma's cancer drug Ampligen to be used in new oncology study

All of the members of the Ocala, Florida-based company’s senior management and board of directors are planning to participate in the rights offering.

The subscription period for the rights offering expires at 5 pm (ET) on March 1, 2019, unless extended by the company.

Maxim Group and Ascendiant Capital Markets LLC have been hired as dealer-managers in the rights offering.

READ: Hemispherx Biopharma started with a Buy rating at Ascendiant Capital Markets

Hemispherx’s flagship products include the Argentina-approved Ampligen, which treats chronic fatigue syndrome and cancer, and the FDA-approved drug Alferon N Injection, a treatment for genital warts.

Hemispherx shares slipped by 2 cents to US$0.18 in morning trade on Wednesday.

Contact Ellen Kelleher at [email protected]

View full HEB profile View Profile

Hemispherx Biopharma Timeline

Related Articles

Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
child
February 08 2019
“If successful, this platform [AP103] has potential in other genetic skin conditions and beyond”
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use